410 related articles for article (PubMed ID: 18702958)
1. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
[TBL] [Abstract][Full Text] [Related]
3. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
4. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
5. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
[TBL] [Abstract][Full Text] [Related]
6. The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients.
Sahin M; Tanaci N; Yucel M; Tutuncu NB; Guvener N
Clin Endocrinol (Oxf); 2007 Sep; 67(3):346-50. PubMed ID: 17524030
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
8. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
9. Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes.
Juntti-Berggren L; Pigon J; Hellström P; Holst JJ; Efendic S
Diabetes Nutr Metab; 2000 Feb; 13(1):7-12. PubMed ID: 10824717
[TBL] [Abstract][Full Text] [Related]
10. The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
Hamada Y; Nagasaki H; Fuchigami M; Furuta S; Seino Y; Nakamura J; Oiso Y
Metabolism; 2013 May; 62(5):734-42. PubMed ID: 23194643
[TBL] [Abstract][Full Text] [Related]
11. The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal.
Frost GS; Brynes AE; Dhillo WS; Bloom SR; McBurney MI
Eur J Clin Nutr; 2003 Feb; 57(2):293-8. PubMed ID: 12571662
[TBL] [Abstract][Full Text] [Related]
12. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
[TBL] [Abstract][Full Text] [Related]
13. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
Meier JJ; Nauck MA; Pott A; Heinze K; Goetze O; Bulut K; Schmidt WE; Gallwitz B; Holst JJ
Gastroenterology; 2006 Jan; 130(1):44-54. PubMed ID: 16401467
[TBL] [Abstract][Full Text] [Related]
15. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects.
de Luis DA; Gonzalez Sagrado M; Conde R; Aller R; Izaola O
Ann Nutr Metab; 2007; 51(2):134-8. PubMed ID: 17536190
[TBL] [Abstract][Full Text] [Related]
16. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
[TBL] [Abstract][Full Text] [Related]
17. Influence of BMI and gender on postprandial hormone responses.
Carroll JF; Kaiser KA; Franks SF; Deere C; Caffrey JL
Obesity (Silver Spring); 2007 Dec; 15(12):2974-83. PubMed ID: 18198306
[TBL] [Abstract][Full Text] [Related]
18. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
Robertson J; Nelson R; Kass P; Neal L
Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
20. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
